Evercore ISI analyst Michael DiFiore initiated coverage of Skye Bioscience (SKYE) with an Outperform rating and $10 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience Earnings Call: Positive Outlook Amid Challenges
- Skye Bioscience Releases Q2 2025 Financial Results
- Skye Bioscience debuts ‘Anatomy of Progress’ nimacimab development update series
- Skye Bioscience participates in panel at Evercore obesity event
- Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks